Claims
- 1. A method for treating chronic obstructive pulmonary disease in a human in need of such therapy, the method comprising administering to the human a therapeutically effective amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, the (R,R)-formoterol containing at least 90% by weight of (R,R)-formoterol and less than 10% by weight of (S,S)-formoterol.
- 2. The method of claim 1, wherein the (R,R)-formoterol is administered by subcutaneous injection, intravenous infusion, inhalation, transdermal delivery or oral administration.
- 3. The method of claim 2, wherein the (R,R)-formoterol or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
- 4. The method of claim 2, wherein the (R,R)-formoterol is administered as the fumarate dehydrate salt.
- 5. The method of claim 2, wherein the (R,R)-formoterol is administered by inhalation and the amount administered is about 1 μg to about 100 μg per day, in single or divided doses.
- 6. The method of claim 5, wherein the amount administered is about 6 μg to about 25 μg per day, in single or divided doses.
- 7. The method of claim 6, wherein the amount administered is about 12 μg to about 25 μg per day, in single or divided doses.
- 8. The method of claim 7, wherein the amount is administered in from two to four divided doses.
- 9. The method of claim 2, wherein the (R,R)-formoterol is administered by orally and the amount administered is about 0.1 mg to about 1 mg per day.
- 10. A method for treating chronic obstructive pulmonary disease in a human in need of such therapy, the method comprising administering to the human a therapeutically effective amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, the (R,R)-formoterol containing at least 90% by weight of (R,R)-formoterol and less than 10% by weight of (S, S)-formoterol, and wherein the amount of (R,R)-formoterol is sufficient to treat COPD, but insufficient to cause adverse effects associated with racemic formoterol.
- 11. The method of claim 10, wherein the (R,R)-formoterol is administered by subcutaneous injection, intravenous infusion, inhalation, transdermal delivery or oral administration.
- 12. The method of claim 11, wherein the (R,R)-formoterol or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
- 13. The method of claim 11, wherein the (R,R)-formoterol is administered as the fumarate dehydrate salt.
- 14. The method of claim 11, wherein the (R,R)-formoterol is administered by inhalation and the amount administered is about 1 μg to about 100 μg per day, in single or divided doses.
- 15. The method of claim 14, wherein the amount administered is about 6 μg to about 25 μg per day, in single or divided doses.
- 16. The method of claim 15, wherein the amount administered is about 12 μg to about 25 μg per day, in single or divided doses.
- 17. The method of claim 16, wherein the amount is administered in from two to four divided doses.
- 18. The method of claim 11, wherein the (R,R)-formoterol is administered by orally and the amount administered is about 0.1 mg to about 1 mg per day.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9107196.9 |
Apr 1991 |
GB |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of pending U.S. patent application Ser. No. 09/927,008, which was filed Aug. 9, 2001 as a continuation of U.S. Ser. No. 09/535,200, which was filed Mar. 27, 2000 as a continuation of U.S. Ser. No. 09/136,109 (now U.S. Pat. No. 6,068,833), which was filed Aug. 18, 1998 as a continuation of U.S. Ser. No. 08/613,382 (now U.S. Pat. No. 5,795,564), which was filed Mar. 7, 1996 as a continuation-in-part of U.S. Ser. No. 08/373,515 (now abandoned), which was filed Jan. 12, 1995 as a continuation-in-part of U.S. Ser. No. 08/222,319 (now abandoned), which was filed Apr. 4, 1994 as a continuation of U.S. Ser. No. 07/927,458 (now abandoned), filed Aug. 10, 1992.
[0002] U.S. Ser. No. 09/136,109 (now U.S. Pat. No. 6,068,833) was also filed as a continuation-in-part of U.S. Ser. No. 08/382,744 (now abandoned), which was filed Feb. 2, 1995 as a continuation of U.S. Ser. No. 08/223,798 (now abandoned), which was filed Apr. 6, 1994 as a continuation of U.S. Ser. No. 07/862,907 (now abandoned), which was filed Apr. 3, 1992 claiming priority under 35 USC 119, of Great Britain application 9107196.9, filed Apr. 5, 1991. The entire content of each of the prior applications is hereby incorporated by reference.
Continuations (7)
|
Number |
Date |
Country |
Parent |
09927008 |
Aug 2001 |
US |
Child |
10457123 |
Jun 2003 |
US |
Parent |
09535200 |
Mar 2000 |
US |
Child |
09927008 |
Aug 2001 |
US |
Parent |
09136109 |
Aug 1998 |
US |
Child |
09535200 |
Mar 2000 |
US |
Parent |
08613382 |
Mar 1996 |
US |
Child |
09136109 |
Aug 1998 |
US |
Parent |
07927458 |
Aug 1992 |
US |
Child |
08222319 |
Apr 1994 |
US |
Parent |
08223798 |
Apr 1994 |
US |
Child |
08382744 |
Feb 1995 |
US |
Parent |
07862907 |
Apr 1992 |
US |
Child |
08223798 |
Apr 1994 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08373515 |
Jan 1995 |
US |
Child |
08613382 |
Mar 1996 |
US |
Parent |
08222319 |
Apr 1994 |
US |
Child |
08373515 |
Jan 1995 |
US |